Friday, 19 April 2024
Galmed Pharmaceuticals Ltd.
20:30 | 17/3/18
StockNewsTimes
Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) - Research analysts at SunTrust Banks cut their Q1 2018 earnings per share estimates for shares of Galmed Pharmaceuticals in a research report issued to clients and investors on Tuesday.
more»
07:45 | 17/3/18
BZ Weekly
683 Capital Management Llc increased its stake in Galmed Pharmaceuticals Ltd (GLMD) by 9.86% based on its latest 2017Q3 regulatory filing with the SEC.
more»
03:03 | 17/3/18
Frisco Fastball
It will be interesting to watch today's trading of shares of Galmed Pharmaceuticals (NASDAQ:GLMD) as Maxim Group upgraded the stock from a “Hold” to a respectable “Buy”.
more»
00:03 | 14/3/18
PR Newswire
TEL AVIV, Israel, March 13, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily ...
more»
Analysts expect Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) to report $-0.23 EPS on March, 22.They anticipate $0.17 EPS change or 42.50 % from last quarter's $-0.4 EPS.
more»
Take Note: Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and ...
more»
01:00 | 6/3/18
PR Newswire
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed? or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic ...
more»
01:00 | 3/3/18
PR Newswire
TEL AVIV, Israel, Mar. 2, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed? or the "Company?), a clinical-stage biopharmaceutical company focused on the development of the liver-targeted SCD1 modulator Aramchol™, a once-daily ...
more»
13:16 | 1/3/18
Simply Wall St
Galmed Pharmaceuticals Ltd's (NASDAQ:GLMD): Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
more»
04:00 | 21/2/18
Seeking Alpha
Growing prevalence of obesity and diabetes have led to NAFLD increasingly become common globally. Indeed, the economic burden of NAFLD is expected to become enormous in the next two decades.
more»
Code | Last | Change |
COMP | 10,321 | 328 | | 3.08% |
DJI | 29,635 | 404 | | 1.34% |
SP500 | 3,583 | 87 | | 2.37% |
DAX | 12,438 | 82 | | 0.67% |
FTSE | 7,488 | 5 | | 0.07% |
NI225 | 22,420 | 408 | | 1.86% |
TWI | 67.27 | 0.00 | | 0.00% |